ClinicalTrials.gg
RecruitingNCT07697482Updated Jul 13, 2026

Respiratory and Relaxation Training in Lower Extremity Lymphedema

An interventional study of Complex Decongestive Therapy and Respiratory and Relaxation Training in Lower Extremity Lymphedema, sponsored by Toros University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Toros University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2026, registered Jul 2026).
  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies in Lymphedema with a site in Turkey — 12 open to participants now, 16 under way, none of them phase 3. Lymphedema · Turkey.

Planned enrollment
10th of 45
60 · median 40
Started
2026
with 8 others
No phase
44 of 65
11 open now
Primary completion
2027-03
later than 12 of 15 live
Registered
62nd of 65
by date

Among the 65 studies in Lymphedema with a site in Turkey, this one is the 10th largest by planned enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2026, is one of 44 with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 62nd registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

12 of the 65 studies in Lymphedema with a site in Turkey are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Lymphedema with a site in Turkey, or all of them as a file.
02

Study summary

This randomized controlled trial aims to investigate the effectiveness of respiratory and relaxation training added to standard complex decongestive therapy (CDT) on muscle oxygenation, functional capacity, and limb volume in patients with lower extremity lymphedema. Participants will be randomly assigned to receive either standard CDT alone or CDT combined with respiratory and relaxation exercises. Outcomes will be assessed before treatment, immediately after treatment, and two months after completion.

Read the detailed description

Lower extremity lymphedema is a chronic condition characterized by impaired lymphatic drainage, limb swelling, pain, reduced physical function, and decreased quality of life. Complex decongestive therapy (CDT) is considered the gold standard treatment; however, additional interventions that may improve physiological and functional outcomes remain under investigation.

Respiratory exercises may facilitate lymphatic return through changes in intrathoracic pressure, whereas relaxation training may reduce sympathetic activation and improve exercise tolerance. Despite these theoretical benefits, there is limited evidence regarding their combined effect on muscle oxygenation in patients with lower extremity lymphedema.

Therefore, this randomized controlled study will evaluate whether adding respiratory and relaxation training to CDT improves muscle oxygenation measured by wearable near-infrared spectroscopy (MOXY), functional capacity assessed with the Six-Minute Walk Test, and limb volume compared with CDT alone.

03

Conditions studied

  • Lower Extremity Lymphedema

Browse trials for

Keywords

  • Lower Extremity Lymphedema
  • Complex Decongestive Therapy
  • Respiratory Training
  • Relaxation Training
  • Muscle Oxygenation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18 years or older.
  • Clinically diagnosed with secondary lower extremity lymphedema.
  • Presence of lower extremity lymphedema for at least 3 months.
  • Able to stand and walk independently to complete the Six-Minute Walk Test.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Acute cellulitis or other active infection within the previous 2-4 weeks.
  • Current or recent deep vein thrombosis (DVT) or uncontrolled peripheral vascular disease.
  • Severe cardiovascular, pulmonary, orthopedic, or neurological conditions that could interfere with participation or outcome assessments.
  • Pregnancy.
  • Skin lesions or irritation preventing placement of the near-infrared spectroscopy (MOXY) sensor.
  • Inability to comply with the study protocol or follow-up assessments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Respiratory and relaxation

    Participants in this group will receive standard Complex Decongestive Therapy (CDT), including manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises, together with respiratory and relaxation training. Respiratory and relaxation exercises will be performed for approximately 10-20 minutes following each CDT session over 15 treatment sessions. Participants will also perform a daily home exercise program.

    Other: Complex Decongestive Therapy · Other: Respiratory and Relaxation Training

  • Active comparator
    Complex Decongestive Therapy

    Participants in this group will receive standard Complex Decongestive Therapy (CDT), including manual lymphatic drainage, compression therapy, skin care, and therapeutic exercises for 15 treatment sessions.

    Other: Complex Decongestive Therapy

Interventions

  • OtherComplex Decongestive Therapy

    Standard Complex Decongestive Therapy consisting of manual lymphatic drainage, compression therapy (bandaging and/or compression garments), skin care education, and therapeutic exercises. Treatment will be provided in 15 sessions according to the standard clinical protocol.

  • OtherRespiratory and Relaxation Training

    A structured respiratory and relaxation program performed after each Complex Decongestive Therapy session. The intervention includes diaphragmatic breathing, thoracic expansion exercises, prolonged expiration breathing, and progressive muscle relaxation or breathing awareness exercises for approximately 10-20 minutes per session. Participants will also be instructed to perform the exercises at home once or twice daily.

06

What researchers measure

Primary outcomes

  1. Change in Muscle Oxygen Saturation

    Muscle oxygen saturation will be assessed using a wearable near-infrared spectroscopy device placed over the vastus lateralis muscle. SmO₂ values will be recorded before, during, and after the Six-Minute Walk Test.

    Time frame: Baseline, immediately after 15 treatment sessions, and 2-month follow-up

Secondary outcomes

  1. Change in Six-Minute Walk Test Distance

    Functional capacity will be assessed using the Six-Minute Walk Test. The total walking distance covered in six minutes will be recorded in meters.

    Time frame: Baseline, immediately after 15 treatment sessions, and 2-month follow-up

  2. Change in Lower Extremity Limb Volume

    Limb volume will be calculated from serial circumference measurements taken at 4-cm intervals from the lateral malleolus using the truncated cone formula.

    Time frame: Baseline, immediately after 15 treatment sessions, and 2-month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 13, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697482
Lead sponsor
Toros University
Responsible party
Idil Esin Unlu (Asst. Prof., Toros University) — Principal investigator
First posted
Jul 13, 2026
Start date
Mar 1, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

İdil Esin Ünlü, Assist. Prof. Dr.
Contact
idil.unlu@toros.edu.tr
+90 506 515 66 22

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion